IMPETUS: Integrated Mechanisms, Phenotypes, and Translational Underpinnings of Chronic Pain after Surgery
Project Number1RM1NS135283-01A1
Former Number1RM1NS135283-01
Contact PI/Project LeaderHAROUTOUNIAN, SIMON Other PIs
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
Chronic postsurgical pain (CPSP) is a major healthcare burden, affecting nearly 20% of patients undergoing major surgery. CPSP is associated with diminished quality of life, mood disturbances, functional impairment, and increases the risk of opioid use disorder. Considerable research suggests that a combination of somatosensory, immune, affective and cognitive mechanisms contribute to CPSP, and that CPSP phenotypes are highly heterogeneous, even after identical surgical procedures. However, most prior research has explored peripheral or central mechanisms in isolation, preventing an integrated insight into underlying biological factors that drive these distinct clinical phenotypes. Preclinical models of CSPS have also failed to capture this phenotypic heterogeneity or meaningful clinical outcome measures, significantly limiting forward translation of basic discoveries. As a result, current strategies for predicting, preventing and treating CPSP are extremely limited. To address this need, we have developed the IMPETUS program that draws expertise from pain neurobiology, clinical pain research, clinical psychology, cognitive neuroscience, immunology, proteomics, genomics, transcriptomics, bioinformatics, machine learning, and pain medicine. Our goal is to gain integrated mechanistic insights into peripheral and central biological processes that contribute to CPSP, and to understand how these processes contribute to CPSP heterogeneity. Aim 1. Characterize peripheral neural and immune mechanisms contributing to CPSP. In patients with CPSP subsequent to abdominal or genitourinary surgery (n=220) and contemporaneous controls (n=100), we will characterize somatosensory profiles of mechanical and thermal sensitivity, the neural and immune milieu at the cutaneous site of injury, and circulating immune host profiles, and compare them with correlates across the same domains in a mouse model of laparotomy. Aim 2. Characterize cognitive and affective mechanisms contributing to CPSP. In patients with CPSP and controls, we will use granular longitudinal data collection methods to characterize affective, cognitive, and activity/sleep measures of CPSP, and compare them with animal model correlates across these domains, using translational outputs of amotivation, punishment-sensitivity, reversal learning task, and actigraphy. Aim 3. Identify and back-translate mechanism-based CPSP phenotypes. Using state-of-the-art machine learning approaches applied to multidimensional data generated in Aims 1 and 2, we will identify discrete CPSP phenotypes, and recapitulate them in animal models for improved translatability. We expect the IMPETUS program to 1) identify distinct somatosensory, neural, immune, affective and cognitive mechanisms that contribute to distinct CPSP phenotypes and explain inter-patient heterogeneity, with cross-species validation; 2) Characterize distinct phenotypic clusters within CPSP to inform personalized patient care and stratified clinical trials for CPSP interventions; and 3) Develop animal models that recapitulate specific clinical phenotypes of CPSP to accelerate for mechanistic exploration and novel therapeutic development.
Public Health Relevance Statement
Chronic postsurgical pain (CPSP) affects 10-20% of patients who undergo surgery and is characterized by marked clinical heterogeneity that underlies the current lack of effective approaches for its prevention or treatment. We aim to understand the biology that drives this heterogeneity, by comprehensively characterizing central and peripheral factors that contribute to CPSP in humans and in rodent models. Our integrated team science approach will identify distinct clinical phenotypes of CPSP and characterize their mechanistic underpinnings, thus narrowing the translational gap toward safe and effective treatment and prevention of CPSP.
National Institute of Neurological Disorders and Stroke
CFDA Code
279
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
18-September-2024
Project End Date
31-August-2027
Budget Start Date
18-September-2024
Budget End Date
31-August-2027
Project Funding Information for 2024
Total Funding
$4,618,885
Direct Costs
$3,377,586
Indirect Costs
$1,241,299
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$4,618,885
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1RM1NS135283-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1RM1NS135283-01A1
Patents
No Patents information available for 1RM1NS135283-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1RM1NS135283-01A1
Clinical Studies
No Clinical Studies information available for 1RM1NS135283-01A1
News and More
Related News Releases
No news release information available for 1RM1NS135283-01A1
History
No Historical information available for 1RM1NS135283-01A1
Similar Projects
No Similar Projects information available for 1RM1NS135283-01A1